Journal profile · INFECTIOUS DISEASES
Therapeutic Advances in Infectious Disease
ISSN 2049-9361 · eISSN 2049-937X · SAGE Publishing · United States
Therapeutic Advances in Infectious Disease: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.8 (journal website); fully open access; APC about USD 2,800; median 129 days to acceptance (101 articles, last 24 months); acceptance rate 37.4% (journal website); 105 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Therapeutic Advances in Infectious Disease is published by SAGE Publishing and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antifungal resistance and susceptibility, HIV/AIDS Research and Interventions and Antibiotic Use and Resistance, together about 22.9% of its articles. Its main subfields are Infectious Diseases. (generated from OpenAlex topic counts and CAS ranking data)
Journal HighlightsLaunched in 2013Gold open access journal – all articles are made freely available online immediately upon publicationRigorous peer reviewListed in PubMed and indexed in Web of Science, Emerging Sources Citation Index (ESCI) and ScopusTherapeutic Advances in Infectious Disease (TAI) is a peer-reviewed open access journal, which focuses on the highest quality research, reviews and scholarly comment on pioneering efforts and innovative studies across all areas of infectious disease. This includes articles examining the social determinants of health. The journal is aimed at an international audience of clinicians, researchers and students/trainees in infectious disease, providing an online forum for publishing the highest quality articles in this field.The journal is a member of the Committee on Publication Ethics (COPE)Diversity, Equity and Inclusion StatementTherapeutic Advances in Infectious Disease (TAI) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the infectious disease community.Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms. Submission informationSubmit your manuscript today at http://mc.manuscriptcentral.com/taid. Please see the Submission Guidelines tab for more information on how to submit your article to the journal.The journal changed its publication mode from subscription to open access in 2019.Open access article processing charge (APC) informationPublication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons licence. The standard APC is $3200. The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.Meet the Editorial TeamClick here to meet the Editorial Team of Therapeutic Advances in Infectious Disease.ContactPlease direct any enquiries to TAInfectiousDisease@sagepub.co.uk.
From the journal's Aims & Scope
Research area (LetPub): INFECTIOUS DISEASES
Editor-in-chief Andrés Henao-MartínezPublisher website
Editorial board by country: 4 in mainland China (about 4%); most named United States 41, United Kingdom 6, India 5, Italy 5, Mainland China 4 (93 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antifungal resistance and susceptibilityMedicine8.5%
- HIV/AIDS Research and InterventionsMedicine8%
- Antibiotic Use and ResistanceImmunology and Microbiology6.5%
- Fungal Infections and StudiesMedicine6.5%
- Tuberculosis Research and EpidemiologyMedicine5%
- COVID-19 Clinical Research StudiesMedicine4.7%
- HIV/AIDS drug development and treatmentMedicine4.5%
- Bacterial Identification and Susceptibility TestingBiochemistry, Genetics and Molecular Biology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Infectious Diseases | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePubMedPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3.8Publisher website ·
- 5-year impact factor (publisher)
- 3.9Publisher website ·
- CiteScore 2026-06
- 5.3LetPub ·
- SJR 2026-06
- 0.95LetPub ·
- SNIP 2026-06
- 1.24LetPub ·
- h-index
- 45OpenAlex ·
- i10-index
- 207OpenAlex ·
- 2-year mean citedness
- 2.46OpenAlex ·
- Self-citation rate
- 2.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 95LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
Articles by year OpenAlex count · 651 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 69 | 69 | 16 |
| 2025 | 105 | 105 | 182 |
| 2024 | 99 | 99 | 474 |
| 2023 | 84 | 84 | 942 |
| 2022 | 80 | 80 | 947 |
| 2021 | 90 | 90 | 1,952 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
129 daysMedian, submission to acceptance · P25–P75 81 days – 183 days
- Acceptance to online
- median 30 days (101 articles)
- Submission to online
- median 167 days
- Sample
- 101 articles with submission and acceptance dates (200 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 9 weeksLetPub ·
- Acceptance rate (publisher)
- 37.4%Publisher website ·
- Submission to first decision
- 6 daysPublisher website ·
- Acceptance to publication
- 32 daysPublisher website ·
- Submission to publication (journal-reported)
- about 9 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,800 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,800 | — | — | |
| LetPub | USD 2,650 | Yes | — | |
| Publisher website | USD 3,200 / USD 5,500 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted9
- original articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- original articlesOriginal Articles. The Editors will consider clinical interventional and observational studies with clearly stated aims, well-reported methodology (including ma…Length not stated
- original research articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- perspectiveView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- review articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
- review articlesReview Articles. These manuscripts are usually commissioned by the Editors but unsolicited reviews will be considered.Length not stated
- scoping reviewsScoping Reviews – These reviews assess the scope of available literature on a topic through comprehensive synthesis.Length not stated
- systematic reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Author contributions
As part of our commitment to ensuring an ethical, transparent and fair peer review and publication process, this journal has adopted CRediT (Contributor Roles Taxonomy). CRediT is a high-level taxonomy, including 14 roles, which is used to describe each author’s individual contributions to the work. You will be asked to list the contribution of each author as part of the submission process. Please…
Source ↗Publisher website ·- Data availability Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- Open access Publishing fees and open access
Therapeutic Advances in Infectious Disease is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the cost of publis…
Source ↗Publisher website ·- Peer review Peer review policy
Single anonymized peer review Model summary
The following summary describes the peer review process for this journal: Identity transparency: Single Anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE Publishing
- Country or region
- United States
- Language
- English
- ISSN
- 2049-9361
- Electronic ISSN
- 2049-937X
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Therapeutic Advances in Infectious Disease
What CAS zone is Therapeutic Advances in Infectious Disease in?
In the 2025 upgraded edition of the CAS Journal Ranking, Therapeutic Advances in Infectious Disease is in Zone 4 of Medicine, and in Zone 4 of the minor category Infectious Diseases. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Therapeutic Advances in Infectious Disease?
The journal's website gives an impact factor of 3.8; this is the journal's own figure, as LetPub lists none for it; CiteScore 5.3, h-index 45.
How long does peer review take at Therapeutic Advances in Infectious Disease?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 129 days (interquartile range 81–183 days); authors report an average review time of about 9 weeks; the journal's website gives an acceptance rate of 37.4%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Therapeutic Advances in Infectious Disease based?
Of the 93 board members whose country the journal's board page names, 4 (about 4%) are in mainland China; the countries named most often are United States (41), United Kingdom (6) and India (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Therapeutic Advances in Infectious Disease?
According to LetPub and DOAJ records, Therapeutic Advances in Infectious Disease is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science and PubMed; that list has not been checked against each database.
Is Therapeutic Advances in Infectious Disease open access, and what is the APC?
Therapeutic Advances in Infectious Disease is a fully open-access journal. APC about USD 2,800.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .